Drug Repurposing Candidates for Triple-Negative Breast Cancer

Discover (after iteration 8) — find something NEW that iteration 8 did not establish about the research question: a pattern, mechanism, candidate or effect that no published work reports. Start from what is still open: Relabel TNBC from documented ER/PR/HER2 status and re-run the screen. Inspect the leave-one-out and basal-only robustness tables; Preregister the MK-1775 hypothesis (label source, drug ID, test, threshold) before analysis. Use nutlin-3a as a control and test on an independent dataset, for example CTRP or PRISM; Test whether the MK-1775 effect holds after adjusting for subtype covariates such as TP53 status and proliferation rate; Prove or refute the alternation by analysing the central mass of U after deletion. Compute exact small cases, state one precise conjecture, and test it on held-out cases, including unequal sizes and ties; Search OEIS and the literature for the integer flip-count sequences. Within the research question, generate the data, state one precise claim, test it on data or cases not used to find it, try to break it, and check its novelty against the literature.